Gene therapy
Murine toxicology assessment of avgn7.2, a novel gene therapeutic for inclusion body myositis and other muscle wasting diseases.
Sarah K Herring, Buel D Rodgers
Published: 202510.1038/s41434-025-00578-x
Abstract
Sporadic inclusion body myositis (IBM) is a highly debilitating muscle degenerative and rare disease of the middle aged and elderly. Because immunosuppressants fail to prevent muscle wasting in IBM patients and can even exacerbate it, drugs like AVGN…
Preview only. Read the full abstract at the source